UK markets closed
  • FTSE 100

    7,032.30
    -46.12 (-0.65%)
     
  • FTSE 250

    22,948.83
    -101.63 (-0.44%)
     
  • AIM

    1,251.11
    +3.84 (+0.31%)
     
  • GBP/EUR

    1.1707
    -0.0030 (-0.26%)
     
  • GBP/USD

    1.3906
    -0.0051 (-0.37%)
     
  • BTC-GBP

    30,042.71
    +1,330.42 (+4.63%)
     
  • CMC Crypto 200

    955.03
    +5.13 (+0.54%)
     
  • S&P 500

    4,395.26
    -23.89 (-0.54%)
     
  • DOW

    34,935.47
    -149.06 (-0.42%)
     
  • CRUDE OIL

    73.81
    +0.19 (+0.26%)
     
  • GOLD FUTURES

    1,812.50
    -18.70 (-1.02%)
     
  • NIKKEI 225

    27,283.59
    -498.83 (-1.80%)
     
  • HANG SENG

    25,961.03
    -354.29 (-1.35%)
     
  • DAX

    15,544.39
    -96.08 (-0.61%)
     
  • CAC 40

    6,612.76
    -21.01 (-0.32%)
     

4basebio UK Societas - Director/PDMR Shareholding

·2-min read

01 July 2021

4basebio UK Societas
(the "Company")
Director’s Dealing

4basebio UK Societas (AIM: 4BB), the specialist life sciences group focused on exploiting its intellectual property in the field of gene therapies and DNA vaccines, announces that, on 1 July 2021, Heikki Lanckriet, chief executive officer, acquired 3,450 ordinary shares at an average price of 467 pence per share on behalf of persons closely associated with him.

As a result of the acquisition of ordinary shares, Heikki Lanckriet’s beneficial holding, including shares held by persons closely associated with him, comprises 1,243,453 ordinary shares representing 10.10 per cent. of the Company’s issued share capital.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further enquiries, please contact:

4basebio UK Societas

+44 (0)12 2396 7943

Heikki Lanckriet, CEO

Cairn Financial Advisers LLP (Nominated Adviser)

+44 (0)20 7213 0880

Jo Turner / Sandy Jamieson

finnCap Ltd (Broker)

+44 (0)20 7220 0500

Geoff Nash/Richard Chambers/Charlotte Sutcliffe

Walbrook PR

+44 (0)20 7933 8780

Anna Dunphy / Paul McManus

Mob: +44 (0)7876 441 001 / +44 (0)7980 541 893

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1. Details of the person discharging managerial responsibilities/person closely associated

a. Name Heikki Lanckriet

2. Reason for notification

a. Position/Status Chief Executive Officer

b. Initial notification/ Amendment Initial

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a. Name 4basebio UK Societas

b. LEI 2138005D5SAG8FIR6G91

4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a. Description of the financial instrument, type Ordinary Shares of instrument

Identification Code ISIN: GB00BLD8ZL39

b. Nature of the transaction Acquisition of ordinary shares

c. Price(s) and volume(s) Volume(s) Price (p)

a. 1,500 467p
b. 650 467p
c. 650 467p
d. 650 467p

d. Aggregated information

- Aggregated Volume 3,450
- Price 467 pence per share

e. Date of the transaction 1/7/2021

f. Place of the transaction London Stock Exchange, AIM

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting